Arecor to re­tain In­hi­brx roy­al­ties in wake of Sanofi ac­qui­si­tion

The com­pa­ny that de­vel­oped the tech­nol­o­gy be­hind Sanofi’s pur­chase of In­hi­brx said that roy­al­ty oblig­a­tions won’t change with the ac­qui­si­tion.

Arecor, a Cam­bridge, UK start­up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER